Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 15/20 | 0.39 |
| ▸ | HTR2C | P28335 | 15/20 | 0.39 |
| ▸ | HTR2B | P41595 | 14/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10218234 | 0.88 | HTR2C (0.49) | XIAPBIRC2CNR2HTR2AHTR2C | |
| SCHEMBL10218533 | 0.86 | TSHR (0.43) | CNR2HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL10218572 | 0.85 | HTR2A (0.41) | CNR2HTR2AHTR2CHTR2BNOTUM | |
| SCHEMBL10218578 | 0.82 | HTR2A (0.45) | HTR2AHTR2CHTR2BNOTUMHTR6 | |
| SCHEMBL10218309 | 0.79 | HTR2C (0.52) | XIAPBIRC2HTR2AHTR2CHTR2B | |
| SCHEMBL10218537 | 0.77 | SPR (0.40) | HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL10218550 | 0.76 | P2RX7 (0.35) | HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL2569302 | 0.74 | HTR2C (0.45) | HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL10218035 | 0.74 | HTR2C (0.48) | HTR2AHTR2CHTR2B | |
| SCHEMBL14700100 | 0.74 | HTR2A (0.38) | HTR2AHTR2CHTR2BHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346816-B2 | 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-24 | — | — | US | disclosed |
| US-9346816-B2 | 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-24 | — | — | US | disclosed |
| US-20120165304-A1 | 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165304-A1 | 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | HTR1A, HTR2C, TPH1 | XIAP 4333/4885BIRC2 4040/4885CNR2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.